nodes	percent_of_prediction	percent_of_DWPC	metapath
Pyrazinamide—XDH—Doxorubicin—kidney cancer	0.194	0.269	CbGbCtD
Pyrazinamide—CYP3A4—Everolimus—kidney cancer	0.106	0.147	CbGbCtD
Pyrazinamide—CYP1A2—Pazopanib—kidney cancer	0.0719	0.0996	CbGbCtD
Pyrazinamide—CYP3A4—Temsirolimus—kidney cancer	0.0717	0.0993	CbGbCtD
Pyrazinamide—CYP1A2—Erlotinib—kidney cancer	0.0513	0.0711	CbGbCtD
Pyrazinamide—CYP1A2—Sorafenib—kidney cancer	0.0417	0.0578	CbGbCtD
Pyrazinamide—CYP3A4—Pazopanib—kidney cancer	0.0377	0.0522	CbGbCtD
Pyrazinamide—CYP3A4—Erlotinib—kidney cancer	0.0269	0.0372	CbGbCtD
Pyrazinamide—CYP3A4—Paclitaxel—kidney cancer	0.0246	0.0341	CbGbCtD
Pyrazinamide—CYP3A4—Sorafenib—kidney cancer	0.0219	0.0303	CbGbCtD
Pyrazinamide—CYP3A4—Vinblastine—kidney cancer	0.0216	0.0299	CbGbCtD
Pyrazinamide—CYP3A4—Vincristine—kidney cancer	0.0212	0.0294	CbGbCtD
Pyrazinamide—CYP3A4—Sunitinib—kidney cancer	0.0177	0.0245	CbGbCtD
Pyrazinamide—CYP3A4—Doxorubicin—kidney cancer	0.0133	0.0184	CbGbCtD
Pyrazinamide—CYP1A2—urine—kidney cancer	0.00567	0.159	CbGeAlD
Pyrazinamide—CYP3A4—urine—kidney cancer	0.0041	0.115	CbGeAlD
Pyrazinamide—XDH—renal system—kidney cancer	0.00398	0.112	CbGeAlD
Pyrazinamide—XDH—kidney—kidney cancer	0.00385	0.108	CbGeAlD
Pyrazinamide—Coagulopathy—Everolimus—kidney cancer	0.0029	0.015	CcSEcCtD
Pyrazinamide—Hepatotoxicity—Erlotinib—kidney cancer	0.00282	0.0146	CcSEcCtD
Pyrazinamide—AOX1—nephron tubule—kidney cancer	0.00278	0.0781	CbGeAlD
Pyrazinamide—Rash maculo-papular—Temsirolimus—kidney cancer	0.00276	0.0143	CcSEcCtD
Pyrazinamide—Tubulointerstitial nephritis—Sorafenib—kidney cancer	0.00256	0.0132	CcSEcCtD
Pyrazinamide—AOX1—renal system—kidney cancer	0.00253	0.071	CbGeAlD
Pyrazinamide—Hepatomegaly—Dactinomycin—kidney cancer	0.00252	0.013	CcSEcCtD
Pyrazinamide—AOX1—kidney—kidney cancer	0.00245	0.0686	CbGeAlD
Pyrazinamide—Hepatotoxicity—Sunitinib—kidney cancer	0.00244	0.0126	CcSEcCtD
Pyrazinamide—Hyperuricaemia—Everolimus—kidney cancer	0.00243	0.0126	CcSEcCtD
Pyrazinamide—Gout—Everolimus—kidney cancer	0.00242	0.0125	CcSEcCtD
Pyrazinamide—AOX1—cortex of kidney—kidney cancer	0.00238	0.0668	CbGeAlD
Pyrazinamide—Hepatotoxicity—Dactinomycin—kidney cancer	0.00231	0.012	CcSEcCtD
Pyrazinamide—Blood uric acid increased—Everolimus—kidney cancer	0.0023	0.0119	CcSEcCtD
Pyrazinamide—Coagulopathy—Dactinomycin—kidney cancer	0.00229	0.0119	CcSEcCtD
Pyrazinamide—AOX1—gonad—kidney cancer	0.00227	0.0637	CbGeAlD
Pyrazinamide—AOX1—cardiac atrium—kidney cancer	0.00227	0.0636	CbGeAlD
Pyrazinamide—Rash maculo-papular—Everolimus—kidney cancer	0.00205	0.0106	CcSEcCtD
Pyrazinamide—Hyperuricaemia—Sunitinib—kidney cancer	0.00203	0.0105	CcSEcCtD
Pyrazinamide—Hepatotoxicity—Gemcitabine—kidney cancer	0.00196	0.0101	CcSEcCtD
Pyrazinamide—Blood uric acid increased—Sunitinib—kidney cancer	0.00192	0.00993	CcSEcCtD
Pyrazinamide—Hepatomegaly—Paclitaxel—kidney cancer	0.00179	0.00926	CcSEcCtD
Pyrazinamide—Dysuria—Temsirolimus—kidney cancer	0.00178	0.00921	CcSEcCtD
Pyrazinamide—Hyperuricaemia—Vincristine—kidney cancer	0.00172	0.00889	CcSEcCtD
Pyrazinamide—Rash maculo-papular—Sunitinib—kidney cancer	0.00171	0.00887	CcSEcCtD
Pyrazinamide—Photosensitivity reaction—Pazopanib—kidney cancer	0.00164	0.00847	CcSEcCtD
Pyrazinamide—Blood uric acid increased—Vincristine—kidney cancer	0.00162	0.0084	CcSEcCtD
Pyrazinamide—Hepatomegaly—Capecitabine—kidney cancer	0.00147	0.0076	CcSEcCtD
Pyrazinamide—CYP1A2—renal system—kidney cancer	0.00139	0.0389	CbGeAlD
Pyrazinamide—Hepatotoxicity—Capecitabine—kidney cancer	0.00135	0.00696	CcSEcCtD
Pyrazinamide—Coagulopathy—Capecitabine—kidney cancer	0.00134	0.00691	CcSEcCtD
Pyrazinamide—Dysuria—Everolimus—kidney cancer	0.00132	0.00685	CcSEcCtD
Pyrazinamide—Rash maculo-papular—Paclitaxel—kidney cancer	0.00115	0.00596	CcSEcCtD
Pyrazinamide—Hepatitis—Everolimus—kidney cancer	0.00113	0.00586	CcSEcCtD
Pyrazinamide—Arthralgia—Temsirolimus—kidney cancer	0.00113	0.00584	CcSEcCtD
Pyrazinamide—Myalgia—Temsirolimus—kidney cancer	0.00113	0.00584	CcSEcCtD
Pyrazinamide—Hepatitis—Erlotinib—kidney cancer	0.00109	0.00566	CcSEcCtD
Pyrazinamide—Myalgia—Pazopanib—kidney cancer	0.00106	0.0055	CcSEcCtD
Pyrazinamide—Arthralgia—Pazopanib—kidney cancer	0.00106	0.0055	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Temsirolimus—kidney cancer	0.00106	0.00548	CcSEcCtD
Pyrazinamide—Anorexia—Temsirolimus—kidney cancer	0.00103	0.00534	CcSEcCtD
Pyrazinamide—CYP3A4—renal system—kidney cancer	0.001	0.0282	CbGeAlD
Pyrazinamide—Thrombocytopenia—Pazopanib—kidney cancer	0.000999	0.00517	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Temsirolimus—kidney cancer	0.000987	0.0051	CcSEcCtD
Pyrazinamide—Anorexia—Pazopanib—kidney cancer	0.000972	0.00503	CcSEcCtD
Pyrazinamide—CYP3A4—kidney—kidney cancer	0.000971	0.0272	CbGeAlD
Pyrazinamide—Hepatitis—Sunitinib—kidney cancer	0.000947	0.0049	CcSEcCtD
Pyrazinamide—Hepatomegaly—Doxorubicin—kidney cancer	0.000947	0.0049	CcSEcCtD
Pyrazinamide—Decreased appetite—Temsirolimus—kidney cancer	0.000941	0.00487	CcSEcCtD
Pyrazinamide—Dysuria—Vincristine—kidney cancer	0.000936	0.00484	CcSEcCtD
Pyrazinamide—Gastrointestinal disorder—Temsirolimus—kidney cancer	0.000935	0.00484	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Pazopanib—kidney cancer	0.000929	0.00481	CcSEcCtD
Pyrazinamide—Ill-defined disorder—Vinblastine—kidney cancer	0.000919	0.00475	CcSEcCtD
Pyrazinamide—Ill-defined disorder—Everolimus—kidney cancer	0.000916	0.00474	CcSEcCtD
Pyrazinamide—Photosensitivity reaction—Vincristine—kidney cancer	0.000913	0.00472	CcSEcCtD
Pyrazinamide—Dyspepsia—Pazopanib—kidney cancer	0.000898	0.00464	CcSEcCtD
Pyrazinamide—Hepatitis—Dactinomycin—kidney cancer	0.000897	0.00464	CcSEcCtD
Pyrazinamide—Malaise—Vinblastine—kidney cancer	0.000893	0.00462	CcSEcCtD
Pyrazinamide—Malaise—Everolimus—kidney cancer	0.00089	0.0046	CcSEcCtD
Pyrazinamide—Decreased appetite—Pazopanib—kidney cancer	0.000887	0.00459	CcSEcCtD
Pyrazinamide—Gastrointestinal disorder—Pazopanib—kidney cancer	0.000881	0.00456	CcSEcCtD
Pyrazinamide—Photosensitivity—Capecitabine—kidney cancer	0.000859	0.00445	CcSEcCtD
Pyrazinamide—Body temperature increased—Temsirolimus—kidney cancer	0.000856	0.00443	CcSEcCtD
Pyrazinamide—Arthralgia—Everolimus—kidney cancer	0.00084	0.00435	CcSEcCtD
Pyrazinamide—Myalgia—Everolimus—kidney cancer	0.00084	0.00435	CcSEcCtD
Pyrazinamide—Discomfort—Vinblastine—kidney cancer	0.000833	0.00431	CcSEcCtD
Pyrazinamide—Discomfort—Everolimus—kidney cancer	0.00083	0.00429	CcSEcCtD
Pyrazinamide—Myalgia—Erlotinib—kidney cancer	0.000811	0.00419	CcSEcCtD
Pyrazinamide—Arthralgia—Erlotinib—kidney cancer	0.000811	0.00419	CcSEcCtD
Pyrazinamide—Hypersensitivity—Temsirolimus—kidney cancer	0.000798	0.00413	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Vinblastine—kidney cancer	0.000792	0.00409	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Everolimus—kidney cancer	0.000789	0.00408	CcSEcCtD
Pyrazinamide—Anorexia—Vinblastine—kidney cancer	0.000771	0.00399	CcSEcCtD
Pyrazinamide—Anorexia—Everolimus—kidney cancer	0.000768	0.00397	CcSEcCtD
Pyrazinamide—Pruritus—Temsirolimus—kidney cancer	0.000766	0.00396	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Erlotinib—kidney cancer	0.000761	0.00394	CcSEcCtD
Pyrazinamide—Dysuria—Paclitaxel—kidney cancer	0.000743	0.00384	CcSEcCtD
Pyrazinamide—Anorexia—Erlotinib—kidney cancer	0.000741	0.00383	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Everolimus—kidney cancer	0.000734	0.0038	CcSEcCtD
Pyrazinamide—Myalgia—Sorafenib—kidney cancer	0.000729	0.00377	CcSEcCtD
Pyrazinamide—Arthralgia—Sorafenib—kidney cancer	0.000729	0.00377	CcSEcCtD
Pyrazinamide—Photosensitivity reaction—Paclitaxel—kidney cancer	0.000725	0.00375	CcSEcCtD
Pyrazinamide—Ill-defined disorder—Dactinomycin—kidney cancer	0.000724	0.00375	CcSEcCtD
Pyrazinamide—Hyperuricaemia—Doxorubicin—kidney cancer	0.000722	0.00374	CcSEcCtD
Pyrazinamide—Pruritus—Pazopanib—kidney cancer	0.000722	0.00373	CcSEcCtD
Pyrazinamide—Dyspepsia—Everolimus—kidney cancer	0.000709	0.00367	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Erlotinib—kidney cancer	0.000708	0.00366	CcSEcCtD
Pyrazinamide—Malaise—Dactinomycin—kidney cancer	0.000704	0.00364	CcSEcCtD
Pyrazinamide—Decreased appetite—Vinblastine—kidney cancer	0.000703	0.00364	CcSEcCtD
Pyrazinamide—Myalgia—Sunitinib—kidney cancer	0.000702	0.00363	CcSEcCtD
Pyrazinamide—Arthralgia—Sunitinib—kidney cancer	0.000702	0.00363	CcSEcCtD
Pyrazinamide—Decreased appetite—Everolimus—kidney cancer	0.0007	0.00362	CcSEcCtD
Pyrazinamide—Gastrointestinal disorder—Everolimus—kidney cancer	0.000695	0.0036	CcSEcCtD
Pyrazinamide—Vomiting—Temsirolimus—kidney cancer	0.000689	0.00356	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Sorafenib—kidney cancer	0.000685	0.00354	CcSEcCtD
Pyrazinamide—Dyspepsia—Erlotinib—kidney cancer	0.000684	0.00354	CcSEcCtD
Pyrazinamide—Rash—Temsirolimus—kidney cancer	0.000683	0.00353	CcSEcCtD
Pyrazinamide—Blood uric acid increased—Doxorubicin—kidney cancer	0.000682	0.00353	CcSEcCtD
Pyrazinamide—Dermatitis—Temsirolimus—kidney cancer	0.000682	0.00353	CcSEcCtD
Pyrazinamide—Decreased appetite—Erlotinib—kidney cancer	0.000676	0.00349	CcSEcCtD
Pyrazinamide—Gastrointestinal disorder—Erlotinib—kidney cancer	0.000671	0.00347	CcSEcCtD
Pyrazinamide—Anorexia—Sorafenib—kidney cancer	0.000666	0.00345	CcSEcCtD
Pyrazinamide—Feeling abnormal—Vinblastine—kidney cancer	0.000666	0.00345	CcSEcCtD
Pyrazinamide—Myalgia—Dactinomycin—kidney cancer	0.000664	0.00344	CcSEcCtD
Pyrazinamide—Feeling abnormal—Everolimus—kidney cancer	0.000664	0.00343	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Sunitinib—kidney cancer	0.000659	0.00341	CcSEcCtD
Pyrazinamide—Discomfort—Dactinomycin—kidney cancer	0.000656	0.0034	CcSEcCtD
Pyrazinamide—Vomiting—Pazopanib—kidney cancer	0.000649	0.00335	CcSEcCtD
Pyrazinamide—Rash—Pazopanib—kidney cancer	0.000643	0.00333	CcSEcCtD
Pyrazinamide—Nausea—Temsirolimus—kidney cancer	0.000643	0.00333	CcSEcCtD
Pyrazinamide—Dermatitis—Pazopanib—kidney cancer	0.000643	0.00332	CcSEcCtD
Pyrazinamide—Anorexia—Sunitinib—kidney cancer	0.000641	0.00332	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Sorafenib—kidney cancer	0.000637	0.00329	CcSEcCtD
Pyrazinamide—Body temperature increased—Everolimus—kidney cancer	0.000637	0.00329	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Dactinomycin—kidney cancer	0.000624	0.00323	CcSEcCtD
Pyrazinamide—Dyspepsia—Sorafenib—kidney cancer	0.000615	0.00318	CcSEcCtD
Pyrazinamide—Body temperature increased—Erlotinib—kidney cancer	0.000614	0.00318	CcSEcCtD
Pyrazinamide—Ill-defined disorder—Gemcitabine—kidney cancer	0.000614	0.00317	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Sunitinib—kidney cancer	0.000613	0.00317	CcSEcCtD
Pyrazinamide—Dysuria—Capecitabine—kidney cancer	0.00061	0.00315	CcSEcCtD
Pyrazinamide—Rash maculo-papular—Doxorubicin—kidney cancer	0.000609	0.00315	CcSEcCtD
Pyrazinamide—Decreased appetite—Sorafenib—kidney cancer	0.000608	0.00314	CcSEcCtD
Pyrazinamide—Anorexia—Dactinomycin—kidney cancer	0.000607	0.00314	CcSEcCtD
Pyrazinamide—Nausea—Pazopanib—kidney cancer	0.000606	0.00313	CcSEcCtD
Pyrazinamide—Gastrointestinal disorder—Sorafenib—kidney cancer	0.000604	0.00312	CcSEcCtD
Pyrazinamide—Malaise—Gemcitabine—kidney cancer	0.000597	0.00309	CcSEcCtD
Pyrazinamide—Hypersensitivity—Vinblastine—kidney cancer	0.000596	0.00308	CcSEcCtD
Pyrazinamide—Photosensitivity reaction—Capecitabine—kidney cancer	0.000595	0.00308	CcSEcCtD
Pyrazinamide—Myalgia—Vincristine—kidney cancer	0.000594	0.00307	CcSEcCtD
Pyrazinamide—Hypersensitivity—Everolimus—kidney cancer	0.000593	0.00307	CcSEcCtD
Pyrazinamide—Dyspepsia—Sunitinib—kidney cancer	0.000592	0.00306	CcSEcCtD
Pyrazinamide—Decreased appetite—Sunitinib—kidney cancer	0.000585	0.00302	CcSEcCtD
Pyrazinamide—Gastrointestinal disorder—Sunitinib—kidney cancer	0.000581	0.003	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Dactinomycin—kidney cancer	0.00058	0.003	CcSEcCtD
Pyrazinamide—Pruritus—Everolimus—kidney cancer	0.00057	0.00295	CcSEcCtD
Pyrazinamide—Arthralgia—Gemcitabine—kidney cancer	0.000563	0.00291	CcSEcCtD
Pyrazinamide—Myalgia—Gemcitabine—kidney cancer	0.000563	0.00291	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Vincristine—kidney cancer	0.000557	0.00288	CcSEcCtD
Pyrazinamide—Discomfort—Gemcitabine—kidney cancer	0.000556	0.00288	CcSEcCtD
Pyrazinamide—Urticaria—Sorafenib—kidney cancer	0.000555	0.00287	CcSEcCtD
Pyrazinamide—Photosensitivity—Doxorubicin—kidney cancer	0.000554	0.00287	CcSEcCtD
Pyrazinamide—Decreased appetite—Dactinomycin—kidney cancer	0.000554	0.00286	CcSEcCtD
Pyrazinamide—Body temperature increased—Sorafenib—kidney cancer	0.000553	0.00286	CcSEcCtD
Pyrazinamide—Pruritus—Erlotinib—kidney cancer	0.00055	0.00284	CcSEcCtD
Pyrazinamide—Anorexia—Vincristine—kidney cancer	0.000542	0.00281	CcSEcCtD
Pyrazinamide—Body temperature increased—Sunitinib—kidney cancer	0.000532	0.00275	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Gemcitabine—kidney cancer	0.000529	0.00273	CcSEcCtD
Pyrazinamide—Feeling abnormal—Dactinomycin—kidney cancer	0.000525	0.00271	CcSEcCtD
Pyrazinamide—Hepatitis—Capecitabine—kidney cancer	0.000522	0.0027	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Vincristine—kidney cancer	0.000518	0.00268	CcSEcCtD
Pyrazinamide—Hypersensitivity—Sorafenib—kidney cancer	0.000515	0.00266	CcSEcCtD
Pyrazinamide—Anorexia—Gemcitabine—kidney cancer	0.000515	0.00266	CcSEcCtD
Pyrazinamide—Vomiting—Vinblastine—kidney cancer	0.000514	0.00266	CcSEcCtD
Pyrazinamide—Ill-defined disorder—Paclitaxel—kidney cancer	0.000514	0.00266	CcSEcCtD
Pyrazinamide—Vomiting—Everolimus—kidney cancer	0.000512	0.00265	CcSEcCtD
Pyrazinamide—Rash—Everolimus—kidney cancer	0.000508	0.00263	CcSEcCtD
Pyrazinamide—Dermatitis—Everolimus—kidney cancer	0.000507	0.00262	CcSEcCtD
Pyrazinamide—Body temperature increased—Dactinomycin—kidney cancer	0.000504	0.0026	CcSEcCtD
Pyrazinamide—Malaise—Paclitaxel—kidney cancer	0.000499	0.00258	CcSEcCtD
Pyrazinamide—Hypersensitivity—Sunitinib—kidney cancer	0.000496	0.00256	CcSEcCtD
Pyrazinamide—Decreased appetite—Vincristine—kidney cancer	0.000495	0.00256	CcSEcCtD
Pyrazinamide—Pruritus—Sorafenib—kidney cancer	0.000495	0.00256	CcSEcCtD
Pyrazinamide—Vomiting—Erlotinib—kidney cancer	0.000494	0.00256	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Gemcitabine—kidney cancer	0.000492	0.00254	CcSEcCtD
Pyrazinamide—Gastrointestinal disorder—Vincristine—kidney cancer	0.000491	0.00254	CcSEcCtD
Pyrazinamide—Rash—Erlotinib—kidney cancer	0.00049	0.00253	CcSEcCtD
Pyrazinamide—Dermatitis—Erlotinib—kidney cancer	0.00049	0.00253	CcSEcCtD
Pyrazinamide—Nausea—Vinblastine—kidney cancer	0.00048	0.00248	CcSEcCtD
Pyrazinamide—Nausea—Everolimus—kidney cancer	0.000478	0.00247	CcSEcCtD
Pyrazinamide—Pruritus—Sunitinib—kidney cancer	0.000476	0.00246	CcSEcCtD
Pyrazinamide—Myalgia—Paclitaxel—kidney cancer	0.000471	0.00244	CcSEcCtD
Pyrazinamide—Arthralgia—Paclitaxel—kidney cancer	0.000471	0.00244	CcSEcCtD
Pyrazinamide—Decreased appetite—Gemcitabine—kidney cancer	0.000469	0.00243	CcSEcCtD
Pyrazinamide—Hypersensitivity—Dactinomycin—kidney cancer	0.000469	0.00243	CcSEcCtD
Pyrazinamide—Gastrointestinal disorder—Gemcitabine—kidney cancer	0.000466	0.00241	CcSEcCtD
Pyrazinamide—Discomfort—Paclitaxel—kidney cancer	0.000466	0.00241	CcSEcCtD
Pyrazinamide—Nausea—Erlotinib—kidney cancer	0.000462	0.00239	CcSEcCtD
Pyrazinamide—Body temperature increased—Vincristine—kidney cancer	0.00045	0.00233	CcSEcCtD
Pyrazinamide—Feeling abnormal—Gemcitabine—kidney cancer	0.000445	0.0023	CcSEcCtD
Pyrazinamide—Vomiting—Sorafenib—kidney cancer	0.000445	0.0023	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Paclitaxel—kidney cancer	0.000443	0.00229	CcSEcCtD
Pyrazinamide—Rash—Sorafenib—kidney cancer	0.000441	0.00228	CcSEcCtD
Pyrazinamide—Dermatitis—Sorafenib—kidney cancer	0.00044	0.00228	CcSEcCtD
Pyrazinamide—Anorexia—Paclitaxel—kidney cancer	0.000431	0.00223	CcSEcCtD
Pyrazinamide—Vomiting—Sunitinib—kidney cancer	0.000428	0.00221	CcSEcCtD
Pyrazinamide—Body temperature increased—Gemcitabine—kidney cancer	0.000427	0.00221	CcSEcCtD
Pyrazinamide—Rash—Sunitinib—kidney cancer	0.000424	0.00219	CcSEcCtD
Pyrazinamide—Dermatitis—Sunitinib—kidney cancer	0.000424	0.00219	CcSEcCtD
Pyrazinamide—Ill-defined disorder—Capecitabine—kidney cancer	0.000422	0.00218	CcSEcCtD
Pyrazinamide—Hypersensitivity—Vincristine—kidney cancer	0.000419	0.00217	CcSEcCtD
Pyrazinamide—Nausea—Sorafenib—kidney cancer	0.000415	0.00215	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Paclitaxel—kidney cancer	0.000412	0.00213	CcSEcCtD
Pyrazinamide—Malaise—Capecitabine—kidney cancer	0.00041	0.00212	CcSEcCtD
Pyrazinamide—Vomiting—Dactinomycin—kidney cancer	0.000405	0.00209	CcSEcCtD
Pyrazinamide—Rash—Dactinomycin—kidney cancer	0.000402	0.00208	CcSEcCtD
Pyrazinamide—Nausea—Sunitinib—kidney cancer	0.0004	0.00207	CcSEcCtD
Pyrazinamide—Dyspepsia—Paclitaxel—kidney cancer	0.000398	0.00206	CcSEcCtD
Pyrazinamide—Dysuria—Doxorubicin—kidney cancer	0.000393	0.00203	CcSEcCtD
Pyrazinamide—Decreased appetite—Paclitaxel—kidney cancer	0.000393	0.00203	CcSEcCtD
Pyrazinamide—Gastrointestinal disorder—Paclitaxel—kidney cancer	0.00039	0.00202	CcSEcCtD
Pyrazinamide—Arthralgia—Capecitabine—kidney cancer	0.000387	0.002	CcSEcCtD
Pyrazinamide—Myalgia—Capecitabine—kidney cancer	0.000387	0.002	CcSEcCtD
Pyrazinamide—Photosensitivity reaction—Doxorubicin—kidney cancer	0.000384	0.00198	CcSEcCtD
Pyrazinamide—Discomfort—Capecitabine—kidney cancer	0.000382	0.00198	CcSEcCtD
Pyrazinamide—Pruritus—Gemcitabine—kidney cancer	0.000382	0.00198	CcSEcCtD
Pyrazinamide—Nausea—Dactinomycin—kidney cancer	0.000378	0.00196	CcSEcCtD
Pyrazinamide—Feeling abnormal—Paclitaxel—kidney cancer	0.000372	0.00193	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Capecitabine—kidney cancer	0.000363	0.00188	CcSEcCtD
Pyrazinamide—Vomiting—Vincristine—kidney cancer	0.000362	0.00187	CcSEcCtD
Pyrazinamide—Urticaria—Paclitaxel—kidney cancer	0.000359	0.00186	CcSEcCtD
Pyrazinamide—Rash—Vincristine—kidney cancer	0.000359	0.00186	CcSEcCtD
Pyrazinamide—Dermatitis—Vincristine—kidney cancer	0.000358	0.00185	CcSEcCtD
Pyrazinamide—Body temperature increased—Paclitaxel—kidney cancer	0.000357	0.00185	CcSEcCtD
Pyrazinamide—Anorexia—Capecitabine—kidney cancer	0.000354	0.00183	CcSEcCtD
Pyrazinamide—Vomiting—Gemcitabine—kidney cancer	0.000343	0.00178	CcSEcCtD
Pyrazinamide—Rash—Gemcitabine—kidney cancer	0.00034	0.00176	CcSEcCtD
Pyrazinamide—Dermatitis—Gemcitabine—kidney cancer	0.00034	0.00176	CcSEcCtD
Pyrazinamide—Nausea—Vincristine—kidney cancer	0.000338	0.00175	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Capecitabine—kidney cancer	0.000338	0.00175	CcSEcCtD
Pyrazinamide—Hepatitis—Doxorubicin—kidney cancer	0.000337	0.00174	CcSEcCtD
Pyrazinamide—Hypersensitivity—Paclitaxel—kidney cancer	0.000333	0.00172	CcSEcCtD
Pyrazinamide—Dyspepsia—Capecitabine—kidney cancer	0.000327	0.00169	CcSEcCtD
Pyrazinamide—Decreased appetite—Capecitabine—kidney cancer	0.000322	0.00167	CcSEcCtD
Pyrazinamide—Nausea—Gemcitabine—kidney cancer	0.000321	0.00166	CcSEcCtD
Pyrazinamide—Gastrointestinal disorder—Capecitabine—kidney cancer	0.00032	0.00166	CcSEcCtD
Pyrazinamide—Pruritus—Paclitaxel—kidney cancer	0.00032	0.00165	CcSEcCtD
Pyrazinamide—Feeling abnormal—Capecitabine—kidney cancer	0.000306	0.00158	CcSEcCtD
Pyrazinamide—Urticaria—Capecitabine—kidney cancer	0.000295	0.00152	CcSEcCtD
Pyrazinamide—Body temperature increased—Capecitabine—kidney cancer	0.000293	0.00152	CcSEcCtD
Pyrazinamide—Vomiting—Paclitaxel—kidney cancer	0.000287	0.00149	CcSEcCtD
Pyrazinamide—Rash—Paclitaxel—kidney cancer	0.000285	0.00147	CcSEcCtD
Pyrazinamide—Dermatitis—Paclitaxel—kidney cancer	0.000285	0.00147	CcSEcCtD
Pyrazinamide—Hypersensitivity—Capecitabine—kidney cancer	0.000273	0.00141	CcSEcCtD
Pyrazinamide—Ill-defined disorder—Doxorubicin—kidney cancer	0.000272	0.00141	CcSEcCtD
Pyrazinamide—Nausea—Paclitaxel—kidney cancer	0.000268	0.00139	CcSEcCtD
Pyrazinamide—Malaise—Doxorubicin—kidney cancer	0.000264	0.00137	CcSEcCtD
Pyrazinamide—Pruritus—Capecitabine—kidney cancer	0.000262	0.00136	CcSEcCtD
Pyrazinamide—CYP1A2—Biological oxidations—ACY1—kidney cancer	0.000262	0.00536	CbGpPWpGaD
Pyrazinamide—XDH—Selenium Micronutrient Network—RELA—kidney cancer	0.000253	0.00518	CbGpPWpGaD
Pyrazinamide—CYP3A4—Estrogen metabolism—GSTM1—kidney cancer	0.000252	0.00516	CbGpPWpGaD
Pyrazinamide—Arthralgia—Doxorubicin—kidney cancer	0.000249	0.00129	CcSEcCtD
Pyrazinamide—Myalgia—Doxorubicin—kidney cancer	0.000249	0.00129	CcSEcCtD
Pyrazinamide—Discomfort—Doxorubicin—kidney cancer	0.000246	0.00127	CcSEcCtD
Pyrazinamide—XDH—Selenium Micronutrient Network—PTGS2—kidney cancer	0.000246	0.00503	CbGpPWpGaD
Pyrazinamide—CYP3A4—Estrogen metabolism—CYP1A1—kidney cancer	0.000239	0.00489	CbGpPWpGaD
Pyrazinamide—Vomiting—Capecitabine—kidney cancer	0.000236	0.00122	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Doxorubicin—kidney cancer	0.000234	0.00121	CcSEcCtD
Pyrazinamide—Rash—Capecitabine—kidney cancer	0.000234	0.00121	CcSEcCtD
Pyrazinamide—Dermatitis—Capecitabine—kidney cancer	0.000234	0.00121	CcSEcCtD
Pyrazinamide—AOX1—Metabolism—ACY1—kidney cancer	0.000229	0.00469	CbGpPWpGaD
Pyrazinamide—CYP3A4—Irinotecan Pathway—APC—kidney cancer	0.000229	0.00468	CbGpPWpGaD
Pyrazinamide—Anorexia—Doxorubicin—kidney cancer	0.000228	0.00118	CcSEcCtD
Pyrazinamide—Nausea—Capecitabine—kidney cancer	0.00022	0.00114	CcSEcCtD
Pyrazinamide—CYP3A4—Xenobiotics—CYP1A1—kidney cancer	0.00022	0.0045	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—CCBL1—kidney cancer	0.000219	0.00447	CbGpPWpGaD
Pyrazinamide—Musculoskeletal discomfort—Doxorubicin—kidney cancer	0.000218	0.00113	CcSEcCtD
Pyrazinamide—CYP1A2—Estrogen Receptor Pathway—JUN—kidney cancer	0.000216	0.00441	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—ACY1—kidney cancer	0.000213	0.00436	CbGpPWpGaD
Pyrazinamide—CYP1A2—Arachidonic acid metabolism—PTGS1—kidney cancer	0.000212	0.00434	CbGpPWpGaD
Pyrazinamide—CYP1A2—Melatonin metabolism and effects—CYP1A1—kidney cancer	0.000212	0.00433	CbGpPWpGaD
Pyrazinamide—CYP3A4—Tamoxifen metabolism—CYP1A1—kidney cancer	0.000211	0.00432	CbGpPWpGaD
Pyrazinamide—Dyspepsia—Doxorubicin—kidney cancer	0.00021	0.00109	CcSEcCtD
Pyrazinamide—CYP3A4—Phase 1 - Functionalization of compounds—ALDH1A1—kidney cancer	0.000209	0.00426	CbGpPWpGaD
Pyrazinamide—Decreased appetite—Doxorubicin—kidney cancer	0.000208	0.00107	CcSEcCtD
Pyrazinamide—Gastrointestinal disorder—Doxorubicin—kidney cancer	0.000206	0.00107	CcSEcCtD
Pyrazinamide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—kidney cancer	0.000202	0.00414	CbGpPWpGaD
Pyrazinamide—CYP3A4—Biological oxidations—ACY1—kidney cancer	0.000202	0.00413	CbGpPWpGaD
Pyrazinamide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUNB—kidney cancer	0.0002	0.00409	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—AMER1—kidney cancer	0.000198	0.00404	CbGpPWpGaD
Pyrazinamide—Feeling abnormal—Doxorubicin—kidney cancer	0.000197	0.00102	CcSEcCtD
Pyrazinamide—AOX1—Metabolism—PDHB—kidney cancer	0.000195	0.00398	CbGpPWpGaD
Pyrazinamide—Urticaria—Doxorubicin—kidney cancer	0.00019	0.000982	CcSEcCtD
Pyrazinamide—Body temperature increased—Doxorubicin—kidney cancer	0.000189	0.000978	CcSEcCtD
Pyrazinamide—AOX1—Metabolism—CCBL1—kidney cancer	0.000183	0.00375	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—PDHB—kidney cancer	0.000181	0.0037	CbGpPWpGaD
Pyrazinamide—Hypersensitivity—Doxorubicin—kidney cancer	0.000176	0.000911	CcSEcCtD
Pyrazinamide—XDH—Metabolism—CCBL1—kidney cancer	0.00017	0.00348	CbGpPWpGaD
Pyrazinamide—Pruritus—Doxorubicin—kidney cancer	0.000169	0.000875	CcSEcCtD
Pyrazinamide—AOX1—Disease—GPC3—kidney cancer	0.000166	0.00339	CbGpPWpGaD
Pyrazinamide—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—kidney cancer	0.000164	0.00335	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—GLIPR1—kidney cancer	0.000159	0.00325	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—PPAT—kidney cancer	0.000159	0.00325	CbGpPWpGaD
Pyrazinamide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—kidney cancer	0.000156	0.00319	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—ST3GAL2—kidney cancer	0.000153	0.00314	CbGpPWpGaD
Pyrazinamide—Vomiting—Doxorubicin—kidney cancer	0.000152	0.000786	CcSEcCtD
Pyrazinamide—Rash—Doxorubicin—kidney cancer	0.000151	0.00078	CcSEcCtD
Pyrazinamide—Dermatitis—Doxorubicin—kidney cancer	0.000151	0.000779	CcSEcCtD
Pyrazinamide—CYP1A2—Phase 1 - Functionalization of compounds—PTGS1—kidney cancer	0.000149	0.00304	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—APRT—kidney cancer	0.000148	0.00302	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—GLIPR1—kidney cancer	0.000148	0.00302	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—PPAT—kidney cancer	0.000148	0.00302	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—FH—kidney cancer	0.000148	0.00302	CbGpPWpGaD
Pyrazinamide—CYP1A2—Aryl Hydrocarbon Receptor—CYP1A1—kidney cancer	0.000146	0.00299	CbGpPWpGaD
Pyrazinamide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CYP1A1—kidney cancer	0.000146	0.00299	CbGpPWpGaD
Pyrazinamide—CYP1A2—Tryptophan metabolism—CYP1A1—kidney cancer	0.000146	0.00299	CbGpPWpGaD
Pyrazinamide—CYP1A2—Phase II conjugation—GSTT1—kidney cancer	0.000144	0.00295	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—PGK1—kidney cancer	0.000144	0.00294	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—SLC5A3—kidney cancer	0.000144	0.00294	CbGpPWpGaD
Pyrazinamide—CYP1A2—Biological oxidations—ALDH1A1—kidney cancer	0.000144	0.00294	CbGpPWpGaD
Pyrazinamide—Nausea—Doxorubicin—kidney cancer	0.000142	0.000735	CcSEcCtD
Pyrazinamide—AOX1—Disease—LDHB—kidney cancer	0.000141	0.00288	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—SFRP2—kidney cancer	0.000141	0.00288	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—GPC3—kidney cancer	0.000139	0.00284	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—FH—kidney cancer	0.000137	0.00281	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—APRT—kidney cancer	0.000137	0.00281	CbGpPWpGaD
Pyrazinamide—CYP1A2—Arachidonic acid metabolism—CYP1A1—kidney cancer	0.000137	0.0028	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—CA2—kidney cancer	0.000135	0.00276	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—ALAD—kidney cancer	0.000132	0.00269	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—TCEB2—kidney cancer	0.000131	0.00269	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—TCEB1—kidney cancer	0.000131	0.00269	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—GPC3—kidney cancer	0.000129	0.00264	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—ST3GAL2—kidney cancer	0.000128	0.00263	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—ALDH1A1—kidney cancer	0.000126	0.00257	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—CA2—kidney cancer	0.000126	0.00257	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—ALAD—kidney cancer	0.000122	0.0025	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—PGK1—kidney cancer	0.00012	0.00246	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—SLC5A3—kidney cancer	0.00012	0.00246	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—ST3GAL2—kidney cancer	0.000119	0.00244	CbGpPWpGaD
Pyrazinamide—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP1A1—kidney cancer	0.000118	0.00242	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—LDHB—kidney cancer	0.000118	0.00241	CbGpPWpGaD
Pyrazinamide—CYP1A2—Oxidation by Cytochrome P450—CYP1A1—kidney cancer	0.000117	0.00239	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—ALDH1A1—kidney cancer	0.000117	0.00239	CbGpPWpGaD
Pyrazinamide—CYP3A4—Phase 1 - Functionalization of compounds—PTGS1—kidney cancer	0.000115	0.00235	CbGpPWpGaD
Pyrazinamide—CYP3A4—Tryptophan metabolism—CYP1A1—kidney cancer	0.000113	0.00231	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—PGK1—kidney cancer	0.000112	0.00229	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—SLC5A3—kidney cancer	0.000112	0.00229	CbGpPWpGaD
Pyrazinamide—CYP3A4—Biological oxidations—ALDH1A1—kidney cancer	0.000111	0.00227	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—LDHB—kidney cancer	0.00011	0.00224	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—RPL14—kidney cancer	0.000107	0.00218	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—CA9—kidney cancer	0.000102	0.00209	CbGpPWpGaD
Pyrazinamide—CYP1A2—Phase II conjugation—GSTP1—kidney cancer	0.0001	0.00204	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—ITPR2—kidney cancer	9.66e-05	0.00198	CbGpPWpGaD
Pyrazinamide—CYP1A2—Phase 1 - Functionalization of compounds—CYP1A1—kidney cancer	9.59e-05	0.00196	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—CA9—kidney cancer	9.52e-05	0.00195	CbGpPWpGaD
Pyrazinamide—CYP1A2—Phase II conjugation—GSTM1—kidney cancer	9.19e-05	0.00188	CbGpPWpGaD
Pyrazinamide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—kidney cancer	9.13e-05	0.00187	CbGpPWpGaD
Pyrazinamide—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—kidney cancer	9.01e-05	0.00184	CbGpPWpGaD
Pyrazinamide—CYP1A2—Aryl Hydrocarbon Receptor—RAF1—kidney cancer	8.99e-05	0.00184	CbGpPWpGaD
Pyrazinamide—CYP1A2—Aryl Hydrocarbon Receptor—RELA—kidney cancer	8.96e-05	0.00183	CbGpPWpGaD
Pyrazinamide—CYP1A2—Cytochrome P450 - arranged by substrate type—POMC—kidney cancer	8.82e-05	0.0018	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—CRABP1—kidney cancer	8.7e-05	0.00178	CbGpPWpGaD
Pyrazinamide—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—kidney cancer	8.7e-05	0.00178	CbGpPWpGaD
Pyrazinamide—CYP1A2—Biological oxidations—GSTT1—kidney cancer	8.44e-05	0.00172	CbGpPWpGaD
Pyrazinamide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CDKN1B—kidney cancer	8.24e-05	0.00168	CbGpPWpGaD
Pyrazinamide—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1B—kidney cancer	8.24e-05	0.00168	CbGpPWpGaD
Pyrazinamide—CYP1A2—Arachidonic acid metabolism—PTGS2—kidney cancer	8.14e-05	0.00166	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—PSMD7—kidney cancer	8.1e-05	0.00166	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—ITPR2—kidney cancer	8.09e-05	0.00165	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—CRABP1—kidney cancer	8.09e-05	0.00165	CbGpPWpGaD
Pyrazinamide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—kidney cancer	8.07e-05	0.00165	CbGpPWpGaD
Pyrazinamide—CYP1A2—Biological oxidations—PTGS1—kidney cancer	7.91e-05	0.00162	CbGpPWpGaD
Pyrazinamide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—kidney cancer	7.85e-05	0.0016	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—ITPR2—kidney cancer	7.52e-05	0.00154	CbGpPWpGaD
Pyrazinamide—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—kidney cancer	7.4e-05	0.00151	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—ACHE—kidney cancer	7.38e-05	0.00151	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—GSTT1—kidney cancer	7.38e-05	0.00151	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—SLC2A1—kidney cancer	7.32e-05	0.0015	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—JUNB—kidney cancer	7.27e-05	0.00149	CbGpPWpGaD
Pyrazinamide—CYP1A2—Phase 1 - Functionalization of compounds—POMC—kidney cancer	7.15e-05	0.00146	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—SCARB1—kidney cancer	6.98e-05	0.00143	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism of lipids and lipoproteins—GLIPR1—kidney cancer	6.97e-05	0.00143	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—PTGS1—kidney cancer	6.91e-05	0.00141	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—GSTT1—kidney cancer	6.86e-05	0.0014	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—ACHE—kidney cancer	6.86e-05	0.0014	CbGpPWpGaD
Pyrazinamide—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—kidney cancer	6.85e-05	0.0014	CbGpPWpGaD
Pyrazinamide—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—kidney cancer	6.81e-05	0.00139	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—PSMD7—kidney cancer	6.78e-05	0.00139	CbGpPWpGaD
Pyrazinamide—CYP3A4—Biological oxidations—GSTT1—kidney cancer	6.51e-05	0.00133	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—SCARB1—kidney cancer	6.49e-05	0.00133	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—BCHE—kidney cancer	6.43e-05	0.00131	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—PTGS1—kidney cancer	6.43e-05	0.00131	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—SLC5A5—kidney cancer	6.35e-05	0.0013	CbGpPWpGaD
Pyrazinamide—CYP1A2—Aryl Hydrocarbon Receptor—MYC—kidney cancer	6.31e-05	0.00129	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—PSMD7—kidney cancer	6.3e-05	0.00129	CbGpPWpGaD
Pyrazinamide—CYP1A2—Aryl Hydrocarbon Receptor—MAPK1—kidney cancer	6.17e-05	0.00126	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—SLC2A1—kidney cancer	6.13e-05	0.00125	CbGpPWpGaD
Pyrazinamide—CYP3A4—Biological oxidations—PTGS1—kidney cancer	6.1e-05	0.00125	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—BCHE—kidney cancer	5.98e-05	0.00122	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—CDKN2B—kidney cancer	5.92e-05	0.00121	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—SLC5A5—kidney cancer	5.9e-05	0.00121	CbGpPWpGaD
Pyrazinamide—CYP1A2—Biological oxidations—GSTP1—kidney cancer	5.85e-05	0.0012	CbGpPWpGaD
Pyrazinamide—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—kidney cancer	5.83e-05	0.00119	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metapathway biotransformation—GSTP1—kidney cancer	5.77e-05	0.00118	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—SLC2A1—kidney cancer	5.7e-05	0.00117	CbGpPWpGaD
Pyrazinamide—CYP3A4—Phase 1 - Functionalization of compounds—POMC—kidney cancer	5.52e-05	0.00113	CbGpPWpGaD
Pyrazinamide—CYP1A2—Biological oxidations—GSTM1—kidney cancer	5.37e-05	0.0011	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metapathway biotransformation—GSTM1—kidney cancer	5.3e-05	0.00108	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—GSTP1—kidney cancer	5.11e-05	0.00105	CbGpPWpGaD
Pyrazinamide—CYP1A2—Biological oxidations—CYP1A1—kidney cancer	5.09e-05	0.00104	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metapathway biotransformation—CYP1A1—kidney cancer	5.02e-05	0.00103	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—ABCB1—kidney cancer	4.84e-05	0.00099	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—GSTP1—kidney cancer	4.75e-05	0.000972	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—HIF1A—kidney cancer	4.73e-05	0.000967	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—TSC2—kidney cancer	4.72e-05	0.000965	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—GSTM1—kidney cancer	4.7e-05	0.000961	CbGpPWpGaD
Pyrazinamide—CYP3A4—Biological oxidations—GSTP1—kidney cancer	4.51e-05	0.000923	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—ABCB1—kidney cancer	4.5e-05	0.00092	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—ACY1—kidney cancer	4.48e-05	0.000916	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—CYP1A1—kidney cancer	4.46e-05	0.000911	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metapathway biotransformation—GSTP1—kidney cancer	4.45e-05	0.00091	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—GSTM1—kidney cancer	4.37e-05	0.000893	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—APC—kidney cancer	4.17e-05	0.000852	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—KIT—kidney cancer	4.17e-05	0.000852	CbGpPWpGaD
Pyrazinamide—CYP3A4—Biological oxidations—GSTM1—kidney cancer	4.15e-05	0.000848	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—CYP1A1—kidney cancer	4.14e-05	0.000847	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metapathway biotransformation—GSTM1—kidney cancer	4.09e-05	0.000836	CbGpPWpGaD
Pyrazinamide—CYP3A4—Biological oxidations—CYP1A1—kidney cancer	3.93e-05	0.000804	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—BRAF—kidney cancer	3.92e-05	0.000801	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metapathway biotransformation—CYP1A1—kidney cancer	3.88e-05	0.000793	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism of lipids and lipoproteins—CRABP1—kidney cancer	3.82e-05	0.000781	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—PDHB—kidney cancer	3.81e-05	0.000779	CbGpPWpGaD
Pyrazinamide—CYP1A2—Biological oxidations—POMC—kidney cancer	3.8e-05	0.000777	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—CCBL1—kidney cancer	3.58e-05	0.000732	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—ACY1—kidney cancer	3.46e-05	0.000707	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—POMC—kidney cancer	3.32e-05	0.000679	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—RAF1—kidney cancer	3.27e-05	0.000669	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism of lipids and lipoproteins—ACHE—kidney cancer	3.24e-05	0.000662	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—ERBB2—kidney cancer	3.24e-05	0.000661	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—MTOR—kidney cancer	3.19e-05	0.000653	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—CD4—kidney cancer	3.19e-05	0.000652	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—PTGS2—kidney cancer	3.16e-05	0.000647	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—GLIPR1—kidney cancer	3.11e-05	0.000635	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—PPAT—kidney cancer	3.11e-05	0.000635	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—POMC—kidney cancer	3.09e-05	0.000631	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism of lipids and lipoproteins—SCARB1—kidney cancer	3.07e-05	0.000627	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS1—kidney cancer	3.04e-05	0.000621	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—CDKN1B—kidney cancer	3e-05	0.000613	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—PDHB—kidney cancer	2.94e-05	0.000601	CbGpPWpGaD
Pyrazinamide—CYP3A4—Biological oxidations—POMC—kidney cancer	2.93e-05	0.000599	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—FH—kidney cancer	2.89e-05	0.00059	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—APRT—kidney cancer	2.89e-05	0.00059	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—CTNNB1—kidney cancer	2.83e-05	0.000579	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—kidney cancer	2.82e-05	0.000577	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—CCBL1—kidney cancer	2.76e-05	0.000565	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—PTEN—kidney cancer	2.76e-05	0.000564	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—GPC3—kidney cancer	2.71e-05	0.000555	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—PTGS2—kidney cancer	2.65e-05	0.000542	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—CA2—kidney cancer	2.64e-05	0.00054	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—ALAD—kidney cancer	2.57e-05	0.000526	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—ST3GAL2—kidney cancer	2.51e-05	0.000514	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—PTGS2—kidney cancer	2.46e-05	0.000504	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—ALDH1A1—kidney cancer	2.46e-05	0.000502	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—GLIPR1—kidney cancer	2.4e-05	0.00049	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—PPAT—kidney cancer	2.4e-05	0.00049	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—MAPK3—kidney cancer	2.36e-05	0.000482	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—PGK1—kidney cancer	2.35e-05	0.000481	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—SLC5A3—kidney cancer	2.35e-05	0.000481	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—PTEN—kidney cancer	2.31e-05	0.000472	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—LDHB—kidney cancer	2.31e-05	0.000472	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—MYC—kidney cancer	2.29e-05	0.000469	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—MAPK1—kidney cancer	2.24e-05	0.000459	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—APRT—kidney cancer	2.23e-05	0.000456	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—FH—kidney cancer	2.23e-05	0.000456	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—PTEN—kidney cancer	2.15e-05	0.000439	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—KRAS—kidney cancer	2.12e-05	0.000433	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—GPC3—kidney cancer	2.1e-05	0.000428	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—CA2—kidney cancer	2.04e-05	0.000417	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—CA9—kidney cancer	2e-05	0.000409	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—ALAD—kidney cancer	1.99e-05	0.000406	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	1.96e-05	0.0004	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—PIK3CA—kidney cancer	1.95e-05	0.000398	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—ST3GAL2—kidney cancer	1.94e-05	0.000396	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—ALDH1A1—kidney cancer	1.89e-05	0.000387	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—PGK1—kidney cancer	1.82e-05	0.000371	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—SLC5A3—kidney cancer	1.82e-05	0.000371	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—LDHB—kidney cancer	1.78e-05	0.000364	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—CRABP1—kidney cancer	1.7e-05	0.000348	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—PIK3CA—kidney cancer	1.63e-05	0.000333	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—ITPR2—kidney cancer	1.58e-05	0.000323	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—CA9—kidney cancer	1.54e-05	0.000316	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—PIK3CA—kidney cancer	1.52e-05	0.00031	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism of lipids and lipoproteins—POMC—kidney cancer	1.46e-05	0.000298	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—ACHE—kidney cancer	1.44e-05	0.000295	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—GSTT1—kidney cancer	1.44e-05	0.000295	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—SCARB1—kidney cancer	1.37e-05	0.000279	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—PTGS1—kidney cancer	1.35e-05	0.000276	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—PSMD7—kidney cancer	1.33e-05	0.000271	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—CRABP1—kidney cancer	1.31e-05	0.000269	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—BCHE—kidney cancer	1.26e-05	0.000257	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—SLC5A5—kidney cancer	1.24e-05	0.000254	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—ITPR2—kidney cancer	1.22e-05	0.00025	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—SLC2A1—kidney cancer	1.2e-05	0.000245	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	1.16e-05	0.000238	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—ACHE—kidney cancer	1.11e-05	0.000228	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—GSTT1—kidney cancer	1.11e-05	0.000228	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—SCARB1—kidney cancer	1.05e-05	0.000215	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—PTGS1—kidney cancer	1.04e-05	0.000213	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—PSMD7—kidney cancer	1.02e-05	0.000209	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	1.01e-05	0.000207	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—GSTP1—kidney cancer	1e-05	0.000204	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—BCHE—kidney cancer	9.7e-06	0.000198	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—SLC5A5—kidney cancer	9.58e-06	0.000196	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—ABCB1—kidney cancer	9.47e-06	0.000194	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—SLC2A1—kidney cancer	9.25e-06	0.000189	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—GSTM1—kidney cancer	9.19e-06	0.000188	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—CYP1A1—kidney cancer	8.71e-06	0.000178	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—GSTP1—kidney cancer	7.72e-06	0.000158	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—ABCB1—kidney cancer	7.31e-06	0.000149	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	7.16e-06	0.000146	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—GSTM1—kidney cancer	7.09e-06	0.000145	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—CYP1A1—kidney cancer	6.72e-06	0.000137	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—POMC—kidney cancer	6.5e-06	0.000133	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—PTGS2—kidney cancer	5.18e-06	0.000106	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—POMC—kidney cancer	5.01e-06	0.000102	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—PTEN—kidney cancer	4.52e-06	9.24e-05	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—PTGS2—kidney cancer	4e-06	8.17e-05	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—PTEN—kidney cancer	3.49e-06	7.13e-05	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—PIK3CA—kidney cancer	3.19e-06	6.52e-05	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—PIK3CA—kidney cancer	2.46e-06	5.03e-05	CbGpPWpGaD
